771 related articles for article (PubMed ID: 19201457)
1. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
2. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
3. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
Lan C; Li Y; Liu J
Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124
[TBL] [Abstract][Full Text] [Related]
6. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
9. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Ivy JJ; Geller M; Pierson SM; Jonson AL; Argenta PA
Gynecol Oncol; 2009 Sep; 114(3):420-3. PubMed ID: 19560189
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
12. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; de Juan A; Redondo A; Martínez S; García Y; Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A
Int J Gynecol Cancer; 2011 Aug; 21(6):1048-55. PubMed ID: 21738038
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
Gemignani ML; Hensley ML; Cohen R; Venkatraman E; Saigo PE; Barakat RR
Gynecol Oncol; 2001 Jan; 80(1):16-20. PubMed ID: 11136563
[TBL] [Abstract][Full Text] [Related]
17. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
18. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
[TBL] [Abstract][Full Text] [Related]
19. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
20. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
Janco JM; Hacker MR; Konstantinopoulos PA; Cannistra SA; Awtrey CS
J Minim Invasive Gynecol; 2011; 18(5):629-33. PubMed ID: 21803662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
